Table 2.
Incidence rate of AKI by type of added NSAIDs in TW patients
| Added NSAIDs | n | AKI cases, n | Total follow-up duration, days | AKI incidence rate [95%CI] (/1,000 person-years) |
|---|---|---|---|---|
| Any type | 41,904 | 54 | 984,848 | 20.0 [14.8 − 25.6] |
| nsCOX-i | 30,968 | 32 | 493,273 | 23.7 [15.5 − 32.6] |
| Acemetacin | 54 | 0 | 471 | - |
| Aluminium flufenamate | 19 | 0 | 124 | - |
| Ampiroxicam | 15 | 0 | 220 | - |
| Diclofenac sodium | 5495 | 5 | 44,931 | 40.6 [8.12 − 81.2] |
| Flurbiprofen | 124 | 0 | 789 | - |
| Flurbiprofen axetil | 1443 | 3 | 2468 | 443.7 [0 − 1035.3] |
| Ibuprofen | 262 | 0 | 2801 | - |
| Indomethacin | 88 | 0 | 292 | - |
| Indomethacin Farnesyl | 58 | 0 | 2272 | - |
| Ketoprofen | 328 | 0 | 2362 | - |
| Loxoprofen sodium hydrate | 21,870 | 18 | 381,522 | 17.2 [9.57 − 25.8] |
| Mefenamic acid | 329 | 0 | 2166 | - |
| Moffezolac | 50 | 0 | 546 | - |
| Naproxen | 150 | 1 | 2995 | 121.9 [0 − 365.6] |
| Oxaprozin | 6 | 0 | 90 | - |
| Piroxicam | 2 | 0 | 120 | - |
| Planoprofen | 187 | 0 | 1868 | - |
| Proglumetacin maleate | 8 | 0 | 364 | - |
| Surindac | 28 | 0 | 952 | - |
| Thiaprofenic acid | 32 | 0 | 200 | - |
| sCOX2-i | 10,425 | 15 | 383,861 | 14.3 [7.61 − 21.9] |
| Celecoxib | 8367 | 12 | 321,744 | 13.6 [6.81 − 21.6] |
| Etodolac | 746 | 1 | 22,677 | 16.1 [0 − 48.3] |
| Lornoxicam | 565 | 0 | 9354 | - |
| Meloxicam | 296 | 1 | 13,376 | 27.3 [0 − 81.9] |
| Nabumetone | 7 | 0 | 156 | - |
| Zartoprofen | 483 | 0 | 8742 | - |
Patients who were initiated on different types or components together were excluded from the analysis
The AKI incidence rate was calculated using the person-year method, dividing the number of AKI cases by the total follow-up period, and presented per 1,000 person-years
Abbreviations: AKI, acute kidney injury. CI, confidence interval. NSAIDs, non-steroidal anti-inflammatory drugs. nsCOX-i: nonselective cyclooxygenase inhibitor. sCOX2-i, cyclooxygenase-2 selective inhibitors. TW, Triple Whammy